CLAIMS

1. Serine protease inhibitor having the formula **(I)**,



(I)

in which

J is H, R^1, R^1-O-C(O)-, R^1-C(O)-, R^1-SO_2-, R^3OOC-$(CHR^2)_p$-, $(R^{2a},R^{2b})N$-CO-$(CHR^2)_p$- or Het-CO-$(CHR^2)_p$-;

D is an amino-acid of the formula -NH-CHR^1-C(O)-, -NR^4-CH[$(CH_2)_qC(O)OR^1$]-C(O)-, -NR^4-CH[$(CH_2)_qC(O)N(R^{2a},R^{2b})$]-C(O)-, -$NR^4$-CH[$(CH_2)_q$C(O)Het]-C(O)-, D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq or D-3-Piq;

E is -NR^2-CH_2- or the fragment



, optionally substituted with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy;

R^1 is selected from (1-12C)alkyl, (2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups may optionally be substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo, OH, CF_3 or halogen, and from (6-14C)aryl, (7-15C)aralkyl, (8-16C)aralkenyl and (14-20C)(bisaryl)alkyl, whereby the aryl groups may optionally be substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF_3 or halogen;

R^2, R^{2a} and R^{2b} are each independently selected from H, (1-8C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which can each be optionally substituted with (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen, and from (6-14C)aryl and (7-15C)aralkyl whereby the aryl groups may optionally be substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen;

R^3 is as defined for R^2 or Het-(1-6C)alkyl;

R^4 is H or (1-3C)alkyl;

X and Y are CH or N with the proviso that they are not both N;

Het is a 4-, 5- or 6-membered heterocycle containing one or more heteroatoms selected from O, N and S;

m is 1 or 2;

p is 1, 2 or 3;

q is 1, 2 or 3;

t is 2, 3 or 4;
or a prodrug;
and/or a pharmaceutically acceptable addition salt and/or solvate thereof.

2. Serine protease inhibitor according to claim 1, wherein
m is 2; X is CH and Y is CH.

3. Serine protease inhibitor according to claim 2, wherein
J is H, R^1, R^1-SO_2-, R^3OOC-$(CHR^2)_p$-, $(R^{2a},R^{2b})N$-CO-$(CHR^2)_p$- or Het-CO-$(CHR^2)_p$-;
D is an amino-acid of the formula -NH-CHR^1-C(O)-,
-NR^4-$CH[(CH_2)_qC(O)OR^1]$-C(O)-, -NR^4-$CH[(CH_2)_qC(O)N(R^{2a},R^{2b})]$-C(O)-,
-NR^4-$CH[(CH_2)_qC(O)Het]$-C(O)-;
E is -N(3-6C)cycloalkyl-CH_2- or the fragment



-N—CH-, optionally substituted with (1-6C)alkyl or (1-6C)alkoxy;
R^1 is selected from (1-12C)alkyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups may optionally be substituted with (3-12C)cycloalkyl, (1-6C)alkoxy or oxo, and from (6-14C)aryl, (7-15C)aralkyl and (14-20C)(bisaryl)alkyl, whereby the aryl groups may optionally be substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF_3 or halogen;
R^2 is H;
R^{2a} and R^{2b} are each independently selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which can each be optionally substituted with (3-6C)cycloalkyl or (1-6C)alkoxy and from (6-14C)aryl and (7-15C)aralkyl whereby the aryl groups may optionally be substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen;
R^3 is selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which can each be optionally substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl whereby the aryl groups may optionally be substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen and from Het-(1-6C)alkyl;
p is 1;
q is 2;
t is 3 or 4.

4. Serine protease inhibitor according to claim 3, wherein

D is an amino-acid of the formula -NH-CHR^1-C(O)- or glutamyl [or an (1-6C)alkylester thereof];

R^1 is selected from (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups may optionally be substituted with (3-12C)cycloalkyl or (1-6C)alkoxy, and from (6-14C)aryl, (7-15C)aralkyl and (14-20C)(bisaryl)alkyl, whereby the aryl groups may optionally be substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy or halogen; and

R^3 is selected from (1-8C)alkyl and (3-8C)cycloalkyl, which can each be optionally substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl whereby the aryl groups may optionally be substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen and from Het-(1-6C)alkyl.

5. Serine protease inhibitor according to claim 4, wherein

J is -CH_2COO(1-6C)alkyl, (3-8C)cycloalkyl, -SO_2-10-camphor, -CH_2CONHphenyl or -CH_2CONH(3-8C)cycloalkyl;

D is D-cyclohexylalaninyl, D-phenylalaninyl, D-diphenylalaninyl or glutamyl [or an (1-6C)alkylester thereof]; and

E is the fragment



-N—CH-, wherein t is 3 or 4.

6. A pharmaceutical composition comprising the serine protease inhibitor of any one of claims 1 to 5 and pharmaceutically suitable auxiliaries.

7. The serine protease inhibitor of any one of claims 1 to 5 for use in therapy.

8. Use of the serine protease inhibitor of any one of claims 1 to 5 for the manufacture of a medicament for treating or preventing thrombin-mediated and thrombin-associated diseases.